Displaying drugs 13276 - 13300 of 14163 in total
Acetylcysteine zidrimer
Investigational
LX1031
LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders. LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels. LX1031 is designed to act locally in the gastrointestinal tract by...
Investigational
Matched Description: … medicinal chemists, and its target was internally identified as a key control point for the regulation of ... LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for ... receptor activation, without affecting serotonin levels in the brain or its central nervous system functions …
Sitravatinib
Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).
Investigational
Matched Iupac: … N'1-(3-fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl …
Matched Description: … Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination ... With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma). …
Matched Description: … Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination ... With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma). …
GSK159797
GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
Investigational
Matched Description: … GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory …
PTI-801
PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
Investigational
Matched Description: … PTI-801 represents a new class of drugs to treat pain. ... It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. ... can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of …
Retaspimycin
Investigational
Matched Iupac: … en-1-yl)amino]-2-azabicyclo[16.3.1]docosa-1(22),4,6,10,18,20-hexaen-9-yl carbamate ... 8S,9S,10E,12S,13R,14S,16R)-13,20,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-[(prop-2- …
Matched Salts cas: … 857402-63-2 …
Matched Salts cas: … 857402-63-2 …
Arylacenamide
Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.
Investigational
Matched Iupac: … N-[(2Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-en-1-yl]-N-ethylcyclohexanamine hydrochloride …
Matched Description: … SRBP-1, [sigma]-2, HSI and its relative SRBP-2. ... Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. …
Matched Description: … SRBP-1, [sigma]-2, HSI and its relative SRBP-2. ... Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. …
Tariquidar
Investigational
Matched Iupac: … N-[2-({4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl}carbamoyl)-4,5-dimethoxyphenyl …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Emfilermin
Investigational
PSN357
PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Investigational
Matched Description: … which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in …
GFT14
GFT14 is a new class of medicaction for treatment of cardiometabolic disease. GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.
GFT14 is destined to improve the condition of patients at risk from cardiovascular disease...
Investigational
Matched Description: … GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of ... GFT14 is a new class of medicaction for treatment of cardiometabolic disease. ... and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides) …
Neocartilage
Neocartilage, a novel cartilage regeneration treatment. Neocartilage is generated from juvenile rather than adult chondrocytes. Neocartilage is the only scaffold-free living cartilage graft on the market.
Investigational
CEP-1347
CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons prior to and after transplantation.
Investigational
Matched Description: … CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults ... leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons prior …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
NCX 701
Nitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.
Investigational
Matched Description: … Nitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol. …
LLL-3348
The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.
Investigational
Matched Description: … The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable …
AEOL-10150
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Investigational
Bisegliptin
Bisegliptin is a compound for the treatment of type 2 diabetes. It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and lowering blood glucose levels without hypoglycemic effects.
Investigational
Matched Iupac: … ethyl 4-({2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl}amino)bicyclo[2.2.2]octane-1-carboxylate …
Matched Description: … Bisegliptin is a compound for the treatment of type 2 diabetes. ... dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of …
Matched Description: … Bisegliptin is a compound for the treatment of type 2 diabetes. ... dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of …
Relacatib
Investigational
Matched Iupac: … (2S)-2-[(1-benzofuran-2-yl)formamido]-4-methyl-N-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)azepan …
Tramiprosate
Investigational
Tesaglitazar
Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Investigational
Matched Iupac: … (2S)-2-ethoxy-3-(4-{2-[4-(methanesulfonyloxy)phenyl]ethoxy}phenyl)propanoic acid …
Matched Description: … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical ... peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in ... trials, however in May 2006 AstraZeneca announced that they had discontinued further development. …
Matched Description: … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical ... peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in ... trials, however in May 2006 AstraZeneca announced that they had discontinued further development. …
Adipiplon
Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.
Investigational
Matched Iupac: … 3-fluoro-2-[1-({2-methyl-8-propyl-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl}methyl)-1H-imidazol-2-yl]pyridine …
Saredutant
Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Investigational
Matched Iupac: … N-[(2S)-2-(3,4-dichlorophenyl)-4-(4-acetamido-4-phenylpiperidin-1-yl)butyl]-N-methylbenzamide …
Matched Description: … Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic …
Matched Categories: … Receptors, Neurokinin-2, antagonists & inhibitors …
Matched Description: … Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic …
Matched Categories: … Receptors, Neurokinin-2, antagonists & inhibitors …
Almorexant
Investigational
Matched Iupac: … (2R)-2-[(1S)-6,7-dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolin-2-yl] ... -N-methyl-2-phenylacetamide …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Ethanolamine
A viscous, hygroscopic amino alcohol with an ammoniacal odor. It is widely distributed in biological tissue and is a component of lecithin. It is used as a surfactant, fluorimetric reagent, and to remove CO2 and H2S from natural gas and other gases.
Experimental
Matched Iupac: … 2-aminoethan-1-ol …
Matched Description: … It is widely distributed in biological tissue and is a component of lecithin. …
Matched Salts cas: … 2002-24-6 ... 54300-24-2 …
Matched Description: … It is widely distributed in biological tissue and is a component of lecithin. …
Matched Salts cas: … 2002-24-6 ... 54300-24-2 …
Displaying drugs 13276 - 13300 of 14163 in total